13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
68 檔
22.7%
As reported in its official Q4 2025 Form 13F filing, Silverarc Capital Management, LLC's tracked investment portfolio stood at $962.2M with 68 total positions.
In Q4 2025, Silverarc Capital Management, LLC adopted a defensive or profit-taking posture, trimming 27 positions and completely liquidating 35 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 7.91% | -1.09% | -21.77% | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 6.14% | -0.01% | +52.78% | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 5.66% | +2.22% | +10.24% | |
| 4 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.44% | -5.91% | EXIT | |
| 5 | CELC | Celcuity Inc | Stock-Other | 5.20% | +1.28% | +322.99% | |
| 6 | NUVL | Nuvalent Inc-a | Stock-Other | 4.35% | -3.71% | EXIT | |
| 7 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.29% | -1.66% | +11.14% | |
| 8 | KOD | Kodiak Sciences Inc | Stock-Other | 3.97% | -1.65% | +2.31% | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.38% | -0.06% | +61.03% | |
| 10 | IMNM | Immunome Inc | Stock-Other | 3.36% | +0.31% | — | |
| 11 | GUTS | Fractyl Health Inc | Stock-Other | 3.01% | +0.06% | -7.17% | |
| 12 | ✓ | Uniqure NV | Stock-Other | 2.40% | -0.83% | EXIT | |
| 13 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.24% | -0.57% | +48.08% | |
| 14 | VCYT | Veracyte Inc | Stock-Other | 2.09% | +1.35% | +51.64% | |
| 15 | CGON | Cg Oncology Inc | Stock-Other | 2.08% | -1.15% | EXIT | |
| 16 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.02% | +0.87% | -63.26% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.88% | +0.64% | +38.64% | |
| 18 | BIIB | Biogen Inc | Stock-Healthcare | 1.84% | +0.13% | -6.23% | |
| 19 | INSM | Insmed Inc | Stock-Healthcare | 1.72% | -0.22% | -65.52% | |
| 20 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.59% | -1.89% | EXIT | |
| 21 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.51% | — | +34.32% | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 1.46% | -2.91% | EXIT | |
| 23 | PFE | Pfizer Inc | Stock-Healthcare | 1.45% | — | — | |
| 24 | BNTC | Benitec Biopharma Inc | Stock-Other | 1.37% | +0.17% | +164.86% | |
| 25 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.32% | +0.96% | NEW | |
| 26 | GH | Guardant Health Inc | Stock-Healthcare | 1.30% | +0.63% | — | |
| 27 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.27% | -0.59% | -42.70% | |
| 28 | PCVX | Vaxcyte Inc | Stock-Other | 0.95% | +0.02% | -52.67% | |
| 29 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.94% | +0.69% | -8.08% | |
| 30 | GOSS | Gossamer Bio Inc | Stock-Other | 0.92% | — | -55.31% | |
| 31 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.85% | -0.41% | — | |
| 32 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.85% | — | -20.68% | |
| 33 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.85% | — | -27.68% | |
| 34 | CERS | Cerus CORP | Stock-Other | 0.81% | +0.46% | +3.63% | |
| 35 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.78% | -0.46% | EXIT | |
| 36 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 37 | ✓ | Compugen LTD | Stock-Other | 0.74% | -0.01% | +5.09% | |
| 38 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.72% | -0.58% | EXIT | |
| 39 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.72% | — | -77.90% | |
| 40 | ERAS | Erasca Inc | Stock-Other | 0.68% | -0.66% | -3.69% | |
| 41 | ✓ | Kalvista Pharmaceuticals Inc | Stock-Other | 0.65% | — | — | |
| 42 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.62% | -0.33% | EXIT | |
| 43 | ✓ | Fulcrum Therapeutics Inc | Stock-Other | 0.62% | -0.16% | — | |
| 44 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.55% | -0.01% | EXIT | |
| 45 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.53% | +0.96% | +5.10% | |
| 46 | SRZN | Surrozen Inc | Stock-Other | 0.49% | -0.43% | EXIT | |
| 47 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.49% | +0.10% | +85.09% | |
| 48 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.48% | — | +18.73% | |
| 49 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 50 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.46% | +0.09% | -36.90% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CELC | Celcuity Inc | +4.6% | +322.99% | Add |
| 2 | COGT | Cogent Biosciences Inc | +4.6% | +52.78% | Add |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | +3.2% | +78.02% | Add |
| 4 | PRAX | Praxis Precision Medicines I | +3% | +61.03% | Add |
| 5 | KOD | Kodiak Sciences Inc | +1.8% | +2.31% | Add |
| 6 | ABVX | Abivax Sa-adr | +1.7% | -21.77% | Trim |
| 7 | GLUE | Monte Rosa Therapeutics Inc | +1.6% | +48.08% | Add |
| 8 | URGN | UroGen Pharma Ltd. | +1.4% | +10.24% | Add |
| 9 | 260 | Centessa Pharmaceuticals-adr | +1.1% | +224.42% | Add |
| 10 | VCYT | Veracyte Inc | +1% | +51.64% | Add |
| 11 | SNDX | Syndax Pharmaceuticals Inc | +0.9% | +38.64% | Add |
| 12 | BNTC | Benitec Biopharma Inc | +0.9% | +164.86% | Add |
| 13 | VRDN | Viridian Therapeutics Inc | +0.8% | +34.32% | Add |
| 14 | GUTS | Fractyl Health Inc | +0.7% | -7.17% | Trim |
| 15 | DNTH | Dianthus Therapeutics Inc | +0.7% | +11.14% | Add |
| 16 | BIIB | Biogen Inc | +0.3% | -6.23% | Trim |
| 17 | ERAS | Erasca Inc | +0.3% | -3.69% | Trim |
| 18 | CTNM | Contineum Therapeutics Inc-a | +0.2% | +85.09% | Add |
| 19 | CERS | Cerus CORP | +0.2% | +3.63% | Add |
| 20 | TRVI | Trevi Therapeutics Inc | +0.2% | -8.08% | Trim |
| 21 | LXEO | Lexeo Therapeutics Inc | +0.2% | -20.68% | Trim |
| 22 | ✓ | Compugen LTD | +0.1% | +5.09% | Add |
| 23 | AVTX | Avalo Therapeutics Inc | +0.1% | -27.25% | Trim |
| 24 | MLYS | Mineralys Therapeutics Inc | +0.1% | +18.73% | Add |
| 25 | ASND | Ascendis Pharma A/S | 0% | -8.08% | Trim |
| 26 | NUVL | Nuvalent Inc-a | 0% | -16.35% | Trim |
| 27 | AARD | Aardvark Therapeutics Inc | — | -0.97% | Trim |
| 28 | RADX | Radiopharm Theranostics LTD | — | — | Unchanged |
| 29 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 30 | CCCC | C4 Therapeutics Inc | 0% | +5.10% | Add |
| 31 | ELUT | Elutia Inc | -0.1% | -3.50% | Trim |
| 32 | TELA | Tela Bio Inc | -0.1% | -4.87% | Trim |
| 33 | SION | Sionna Therapeutics Inc | -0.2% | -61.89% | Trim |
| 34 | ABEO | Abeona Therapeutics Inc | -0.3% | -36.90% | Trim |
| 35 | AMLX | Amylyx Pharmaceuticals Inc | -0.4% | -27.68% | Trim |
| 36 | CLDX | Celldex Therapeutics Inc | -0.5% | -45.24% | Trim |
| 37 | OLMA | Olema Pharmaceuticals Inc | -0.5% | -77.90% | Trim |
| 38 | CMPX | Compass Therapeutics Inc | -0.6% | -62.90% | Trim |
| 39 | PCVX | Vaxcyte Inc | -0.6% | -52.67% | Trim |
| 40 | GOSS | Gossamer Bio Inc | -0.8% | -55.31% | Trim |
| 41 | RAPP | Rapport Therapeutics Inc | -0.8% | -95.26% | Trim |
| 42 | CGON | Cg Oncology Inc | -1.4% | -43.42% | Trim |
| 43 | ✓ | Ultragenyx Pharmaceutical In | -1.8% | -79.17% | Trim |
| 44 | ORIC | Oric Pharmaceuticals Inc | -1.9% | -42.70% | Trim |
| 45 | INSM | Insmed Inc | -2.3% | -65.52% | Trim |
| 46 | RYTM | Rhythm Pharmaceuticals Inc | -3% | -63.26% | Trim |
| 47 | QURE | uniQure N.V. | -3.2% | -72.30% | Trim |
| 48 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 49 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 50 | ✓ | United Therapeutics CORP Del | — | EXIT | Sold out |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 68 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, COGT, URGN) accounted for 22.7% of total reported equity market value during Q4 2025.
Top New Position Initiated
IMNM
市值: $24.2M
Top Position Liquidated / Trimmed
RNAGBP
前期市值: $36.8M
During Q4 2025, Silverarc Capital Management, LLC's top holdings by market value included ABVX (7.9%)、COGT (6.1%)、URGN (5.7%). The largest single position, ABVX, represented 7.9% of total portfolio value.
In Q4 2025, Silverarc Capital Management, LLC made 101 total portfolio adjustments, initiating 21 new buys, adding to 18 positions, trimming 27 holdings, and fully liquidating 35 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.